Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 4/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 9/20 | 0.45 |
| ▸ | CNR1 | P21554 | 6/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4849757 | 0.78 | HRH2 (0.47) | HRH2HTR2AHTR2CHTR2BCNR2 | |
| SCHEMBL5799049 | 0.75 | HRH2 (0.44) | HRH2HTR2AHTR2CHTR2BCNR2 | |
| SCHEMBL5204952 | 0.75 | HRH2 (0.55) | HRH2HTR2AHTR2CHTR2BCNR2 | |
| SCHEMBL5203433 | 0.74 | TPSAB1 (0.50) | HRH2HTR2AHTR2CHTR2BCNR2 | |
| SCHEMBL5202233 | 0.73 | HRH2 (0.41) | HRH2HTR2AHTR2CHTR2B | |
| SCHEMBL4858049 | 0.72 | MEN1 (0.52) | HTR2AHTR2CHTR6 | |
| SCHEMBL5205873 | 0.71 | HRH2 (0.51) | HRH2HTR2AHTR2CHTR2BCNR2 | |
| SCHEMBL27559062 | 0.70 | HRH2 (0.59) | HRH2HTR2AHTR2CHTR2BCNR2 | |
| SCHEMBL5205803 | 0.70 | HRH2 (0.50) | HRH2HTR2AHTR2CHTR2BCNR2 | |
| SCHEMBL6781923 | 0.69 | HRH2 (1.00) | HRH2HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368470-B2 | Substituted 3-pyrrolidine-indole derivatives | GRUENENTHAL GMBH (DE) | 2008-05-06 | — | — | US | claimed |
| EP-1654253-B1 | SUBSTITUTED 3-PYRROLIDIN-INDOLE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2007-01-03 | — | — | EP | claimed |
| US-20050096376-A1 | Substituted 3-pyrrolidine-indole derivatives | GRUENENTHAL GMBH (DE) | 2005-05-05 | — | — | US | claimed |
| US-7368470-B2 | Substituted 3-pyrrolidine-indole derivatives | GRUENENTHAL GMBH (DE) | 2008-05-06 | — | — | US | disclosed |
| EP-1654253-B1 | SUBSTITUTED 3-PYRROLIDIN-INDOLE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2007-01-03 | — | — | EP | disclosed |
| US-20050096376-A1 | Substituted 3-pyrrolidine-indole derivatives | GRUENENTHAL GMBH (DE) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096376-A1 | Substituted 3-pyrrolidine-indole derivatives | OPRD1, OPRK1, TPH1 | HRH2 973/4885HTR2A 12/4885HTR2C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.